Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Updates 'Contact for Potential Acquisition of ' R&D Programs' Section on its Corporate Website

04/13/2021 | 08:42am EDT

Astellas Pharma Inc. ('Astellas') updated the information about Astellas terminated R&D programs on 'Contact for Potential Acquisition of Astellas' R&D programs' section on its corporate website.

https://www.astellas.com/en/contact-r-and-d-programs

Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R&D that uses external resources and redevelopment for other indications. This endeavor is part of this effort, and the company is planning to post some of its terminated programs on the website successively to widely recruit potential parties. Through this, we hope to deliver new treatment options for patients suffering from diseases with high unmet medical needs.

Contact:

Location: 2-5-1, Nihonbashi-Honcho

Chuo-Ku, Tokyo 103-8411

Japan

Main phone line: +81-3-3244-3000

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
PU
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
BU
06/29ASTELLAS PHARMA : Corporate Governance Report
PU
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Ad..
PU
More news
Financials
Sales 2022 1 320 B 12 049 M 12 049 M
Net income 2022 203 B 1 849 M 1 849 M
Net cash 2022 523 B 4 770 M 4 770 M
P/E ratio 2022 17,3x
Yield 2022 2,58%
Capitalization 3 534 B 32 266 M 32 257 M
EV / Sales 2022 2,28x
EV / Sales 2023 2,04x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 907,00 JPY
Average target price 2 482,31 JPY
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.19.64%32 066
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750